Leiden University Medical Center
- Address
- lock Available on a paid plan
Neoplasms – Cancer Research
The Leiden University Medical Center is advancing knowledge in blood‑related cancers, with a focus on high risk diffuse large B-cell lymphoma. Researchers are testing innovative treatment combinations to improve long‑term survival and reduce relapse rates.
- Atezolizumab consolidation therapy
- R-CHOP induction regimen
- 2‑year disease‑free survival evaluation
Three investigators are conducting three independent trials, all within a non‑commercial hospital environment, to generate robust data for future therapeutic guidelines.
Diffuse Large B‑Cell Lymphoma Clinical Studies
In the field of high risk diffuse large B-cell lymphoma, the site evaluates patients who achieve complete metabolic remission after standard chemotherapy, aiming to determine the added benefit of checkpoint‑inhibitor consolidation.
- Metabolic remission as a surrogate endpoint
- Feasibility of immunotherapy after R-CHOP
- Long‑term outcome monitoring
Located in Leiden, Netherlands, the department leverages its expertise in hematology to generate evidence that may shape future treatment standards for this aggressive lymphoma.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Leiden University Medical Center
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A non-inferiority, randomised and controlled trial to compare the safety, tolerability and preliminary efficacy between standard and Torque Teno virus-guided immunosuppression in stable adult kidney transplant recipients with low immunological risk in the first year after transplantation | Medical University Of Vienna | Phase II | Not Recruiting | Aug 2022 | May 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2018-08-28 | 2018-08-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.